Weil, Wachtell, Shearman, Simpson, Latham and Davis Polk all got the year's second quarter off to a strong start by grabbing roles on one of two big pharmaceutical deals announced Monday: Irish specialty drugmaker Mallinckrodt's $5.6 billion cash-and-stock purchase of California's Questcor Pharmaceuticals and India's Sun Pharmaceutical Industries' $3.2 billion buy of struggling rival Ranbaxy Laboratories.
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
For questions call 1-877-256-2472 or contact us at email@example.com